Dear Editor-in-Chief
====================

Diabetes is one of the most important noncommunicable diseases, through its effects on many body organs. It is the major risk factor for cardiovascular diseases, kidney failure, blindness and increases risk of death. Incidence and prevalence of this disease have risen at increasing rate during the past decades ([@B1]). The number of people with diabetes will increase from 415 million in 2015 to 642 million in 2040 ([@B2]). The maximum prevalence of diabetes occurred in countries with low and average income levels ([@B3]).

Considering its increasing rate in the Eastern Mediterranean Region, it will rise from 9.7% in 2014 to 11.6% in 2040 ([@B1], [@B4]). The screening program for diabetes was implemented in the rural regions of Iran in 2005 and 2008 among the population aged over 30 years. Identification of patients has taken place opportunistically in rural regions since 2011 and the people with diabetes are entered into the country's system of diabetes surveillance. In this program, patients were visited once every three months by a doctor and sent to laboratories for the HbA1c and fasting blood sugar tests. Results of the National Program for Prevention and Control of Diabetes in the Rural Regions in the second quarter of 2015 recorded in the portal of the Department of Non-Communicable Diseases at the Ministry of Health indicate that, among the 12 million rural population covered by these universities, at least 364,000 diabetes patients are under surveillance, and 67% of the male patients and 72% of the female patients have been taken care during this period.

About 74% of these patients had HbA1c levels less than 8, while 37% of these patients had HbA1c levels less than 7, and 50% of these patients had ideal fasting blood sugar levels (70--130) ([Table 1](#T1){ref-type="table"}).

###### 

Results of diabetes surveillance rural population of Iran

  ***Sex***   ***Population\>30***   ***Number of patients***   ***Number of patients cared by GP***   ***Number of FBS test***   ***FBS 70--130***   ***Number of HbA1C tests***   ***HbA1C\< 7***   ***HbA1C\< 8***
  ----------- ---------------------- -------------------------- -------------------------------------- -------------------------- ------------------- ----------------------------- ----------------- -----------------
  Male        6182836                110776                     74124 (67%)                            54286                      27966 (52%)         23766                         8765 (37%)        17630(74%)
  Female      6050644                253477                     181531(72%)                            127915                     62717 (49%)         54444                         20562 (38%)       40172(74%)
  Total       12233480               364253                     255655 (70%)                           182201                     90683(50%)          78210                         29327 (37%)       57802(74%)

Data are shown as frequency (percentage)

In patients with diabetes, the treatment goal is to reduce HbA1c levels to 7% or lower. One percent decrease in HbA1C level reduces cardiovascular complications by 37%, myocardial infarction by 14%, and mortality resulting from diabetes by 21%. This indicates the importance of controlling the HbA1c level ([@B5]).
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